Bernard-Soulier Syndrome (BSS)

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 16 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Article Summary

Bernard-Soulier syndrome (BSS) is a rare autosomal-recessive inherited mucocutaneous bleeding disorder of blood clotting (coagulation) characterized by unusually large platelets, and unusually giant low platelet count (thrombocytopenia), and prolonged bleeding time (difficulty in clotting) bleed excessively and incur spontaneous ecchymoses. BSS involves a defect of the GPIb-IX-V complex, an essential platelet receptor complex that principally binds with the von Willebrand factor (vWF). Affected individuals tend to...

Key Takeaways

  • This article explains Symptoms in simple medical language.
  • This article explains Causes in simple medical language.
  • This article explains Diagnosis in simple medical language.
  • This article explains Treatment in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Bernard-Soulier syndrome (BSS) is a rare autosomal-recessive inherited mucocutaneous bleeding disorder of blood clotting (coagulation) characterized by unusually large platelets, and unusually giant low platelet count (thrombocytopenia), and prolonged bleeding time (difficulty in clotting) bleed excessively and incur spontaneous ecchymoses. BSS involves a defect of the GPIb-IX-V complex, an essential platelet receptor complex that principally binds with the von Willebrand factor (vWF). Affected individuals tend to bleed excessively and bruise easily. Most cases of Bernard-Soulier syndrome are inherited in an autosomal recessive genetic pattern.

Symptoms

The symptoms of Bernard-Soulier syndrome, which are typically apparent at birth and continue throughout life, may include the tendency to bleed excessively from cuts and other injuries, nosebleeds (epistaxis), and/or an unusually heavy menstrual flow in women. Some babies and children with BSS have no symptoms and the disorder does not present until adult life. People with this disease also bruise easily and the bruises tend to linger. Bleeding from very small blood vessels under the skin (subcutaneous) may cause small or widespread areas of small red or purple-colored spots (purpura or petechiae). Spontaneous bruising, gum bleeding, epistaxis, and heavy menstrual bleeding are common presentations

Bernard–Soulier syndrome often presents as a bleeding disorder with symptoms of:[rx]

  • Perioperative (and postoperative) bleeding
  • Bleeding gums
  • Bruising
  • Epistaxis (nosebleeds)
  • Abnormal bleeding (from small injuries)
  • Unusual menstrual periods

Causes

BSS is a genetic disorder that affects the ability of the platelets in the circulating blood to bind with a damaged blood vessel and hence clot blood. These platelets are missing an essential protein called the glycoprotein Ib-IX-V complex (GPIb). The Gp1b complex is composed of 4 protein subunits that bind closely together (GP1b-alpha, GP1b-beta, GP9, and GP5). BSS is caused by mutations in one of the Gp1b complex genes- so far mutations have been found in BP1b-alpha, Gp1b-beta, and GP9 but no mutations have been found in GP5. Normally the GP1b complex sticks out of the platelet’s surface and binds with another protein found in the circulating blood called von Willebrand factor. If one of these proteins is missing or abnormal, they cannot bind correctly to begin the clotting process and excessive bleeding results.

Bernard-Soulier syndrome is usually inherited in an autosomal recessive genetic pattern. Recessive genetic disorders occur when an individual inherits an abnormal gene from each parent. If an individual receives one normal gene and one abnormal gene for the disease, the person will be a carrier of the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the abnormal gene and, therefore, have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier, like the parents, is 50% with each pregnancy. The chance for a child to receive normal genes from both parents is 25%. The risk is the same for males and females.

BSS is the result of genetic mutations encoding for GPIb-alpha (GPIBA), GPIB-beta (GPIBB), and GPIX (GP9), which are 3 of the four subunits that make the GPIb-IX-V complex. Nearly 112 mutations were identified in a study of nearly 211 families with BSS. The mutations were mainly identified in the GP1BA (28%), GP1BB (28%), or GP9 (44%) genes. These mutations are heterogeneous and could be nonsense, missense, frameshift, deletion, or insertion. The majority of these mutations are inherited in an autosomal recessive pattern; however, rare cases of autosomal dominant inheritance have been reported. Patients with mutations in both alleles (autosomal recessive inheritance) are referred to as having biallelic BSS (BSS), and those with a mutation in only a single allele (autosomal dominant inheritance) are often referred to as monoallelic BSS (BSS).

Diagnosis

The diagnosis of Bernard-Soulier syndrome is made by a combination of blood testing to reveal whether platelets are at abnormally low levels (platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia), microscopic examination to determine the presence of abnormally large platelets and irregularly shaped platelets, and a test called ‘flow cytometry, which can measure the level of expression of the missing protein ion the outside of platelets affected by Bernard-Soulier syndrome. In recent years, most families are offered molecular genetic testing to identify which gene carries the mutations.

BSS diagnosis is confirmed by Flow cytometric analysis of platelets showing defective binding with CD42a (GPIX), CD42b (GP Ibα), CD42c (GP Ibβ), and CD42d (GPV) antibodies. The defective fragments of GP Ib-IX-V complex after separating with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) may be identified by immunoblotting

History and Physical

The typical presentation of Bernard-Soulier syndrome starts at birth and continues throughout life. It is characterized by bleeding from different sites, epistaxis, cutaneous bleeding, hemorrhage post-trauma, e.g., brain hemorrhage after head trauma, prolonged bleeding after dental procedures, and heavy menstrual bleeding in females. More rarely reported symptoms are gastrointestinal bleeding and hematuria. Clinical features could be limited to unexplained purpura or bruising only. On the other hand, bleeding could be fatal in about 16% of reported cases. Spontaneous intracranial hemorrhages or intraarticular hemorrhages are not common. Fatalities from BSS are very rare.

Complete blood count (CBC) was performed on EDTA blood through Sysmex Kx 2100 automated analyzer Peripheral smear for each sample was also examined. Bleeding time was done by Ivy’s method and the established reference range was 2-9 minutes. Patients with suggestive history and screening tests were evaluated by Platelet Aggregometry. Blood was drawn from a forearm venipuncture with minimal venous occlusion for the platelet aggregation test. The blood samples were processed within two hours of collection.

The citrated blood was centrifuged at 1000-1200 rpm for 7-8 minutes to obtain platelet-rich plasma and collected in a separate tube. The remaining sample was centrifuged at 3500 rpm to obtain platelet-poor plasma (PPP). The platelet count of PRP was adjusted between 200-400 x 109/L. PRP was allowed to stand at room temperature for 30 minutes.

Platelet aggregation was performed by turbidometric technique on Chronolog aggregometer by adding 10 µm/ml Adenosine diphosphate (ADP) and 1.25 mg/ml Ristocetin and collagen 2 μg/ml, Epinephrine 10 µm/ml in 250µL PRP in separate cuvettes. Platelet aggregation was recorded as the percentage change in light transmission after three minutes (maximal platelet aggregation percentage). Samples from normal patients were treated similarly to prepare PRP and PPP and ran simultaneously to serve as controls. The percentage of aggregation was compared with controls and the normal reference ranges provided by the company.

The patients with BSS who present in adulthood are usually those with BSS. Such patients have less bleeding episodes due to preserved platelet numbers. A significant monoallelic mutation is the ‘Ala156Val’ mutation in the GPIB-alpha, called the Bolzano mutation. Although most patients will only have mild platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia, and infrequent bleeding episodes, a few patients have been described where the bleeding was very severe. Similarly, other mutations have also been described where only mild platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia was noted with mild bleeding episodes.

The International Society on Thrombosis and Haemostasis Bleeding Assessment Tool (ISTH-BAT) is a useful assessment tool for assessing bleeding disorders. Its utility was tested in a small study, including patients with known inherited platelet disorders. The study demonstrated a specificity of 100%, a positive predictive value of 90%, and a negative predictive value of 100% with the use of this assessment tool. Similarly, other bleeding assessment tools like Molecular and Clinical Markers for the Diagnosis and Management of type 1-VWD and World Health Organization Bleeding Assessment Tool are also present for similar purposes. An electronic version of MCMDM-type-1 vWD was developed in 2010.

BSS should be considered in the diagnosis: Differential diagnosis is a list of possible conditions that may explain symptoms. সহজ বাংলা: একই লক্ষণের সম্ভাব্য রোগের তালিকা।" data-rx-term="differential diagnosis" data-rx-definition="Differential diagnosis is a list of possible conditions that may explain symptoms. সহজ বাংলা: একই লক্ষণের সম্ভাব্য রোগের তালিকা।">differential diagnosis of any patient who presents with a prolonged bleeding history, especially if the bleeding history started from early childhood.

Most patients with BSS have a platelet count between 20 to 100 billion/L. However, a count as low as 10 x 10^9/L has been reported. The peripheral smear would usually present with platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia and large platelets. The bleeding time is significantly prolonged. The platelet function analyzer (PFA-100) closure time is prolonged, usually in the adenosine-diphosphate (ADP) and epinephrine cartridges.

The platelet aggregation studies (also called light transmission aggregometry) demonstrate a reduced response to ristocetin that is not corrected by the addition of normal plasma. This feature helps to distinguish BSS from von Willebrand disease (VWD). The responses to ADP, collagen and arachidonic acid are normal. However, in a few patients, platelet aggregation in response to thrombin is reduced.

Flow cytometry of platelet glycoprotein is a confirmatory test. It demonstrates marked reduction of CD42a (GPIX) and CD42b (GPIb-alpha). Since flow cytometry requires only small volumes of blood, this is an appropriate test for neonates, infants, and young children. Molecular genetics can identify genetic abnormalities and identify affected family members as well.

In patients with mBSS, specifically, in those with Bolzano mutation or other similar mutations, the GPIb-IX-V complex is present in normal numbers, albeit is defective and cannot bind to VWF. In such patients, the near absent ristocetin-induced platelet aggregation serves as a good diagnostic tool. It is crucial to maintain a high index of suspicion in such patients and pursue molecular testing.

Treatment

Platelet transfusion is used to treat Bernard-Soulier syndrome when surgery is necessary or when there is a risk of life-threatening hemorrhage. Some patients with Bernard-Soulier syndrome become resistant (refractory) to platelet transfusions because they develop antibodies against the GPIb protein- to reduce this risk it is now recommended that specially selected platelet transfusions (from HLA-matched single donors) should be used. Where HLA-matched platelets are not available, leucocyte-depleted platelets can be used (these are platelet transfusions from which contaminating white blood cells-leucocytes- have been removed). People with this disorder should not take aspirin or other related drugs because these medications affect the blood’s ability to clot (platelet aggregation). It is suggested that acetaminophen, which is present in medications such as Tylenol, is used for the relief of mild pain. Antifibrinolytic agents (drugs which delay the breakdown of blood clots) are often useful to help reduce bleeding after a minor surgery (eg dental surgery) or for prolonged nosebleeds. The most commonly used antifibrinolytic drug is tranexamic acid (also known as epsilon aminocaproic acid).

Preventive Care

  • Patients diagnosed with BSS should be educated extensively about the risks of bleeding. They should carry ‘alert cards’ or wear ‘alert bracelets’ clearly identifying the diagnosis of BSS. They should be registered with a center that can provide emergent treatment 24 hours a day should they present with a bleeding episode. The patients should also be educated on maintaining dental hygiene, avoiding high-risk sports (especially contact sports), and applying pressure for epistaxis.
  • Patients, their family members, and their providers should be advised extensively on which medications can increase the risk of bleeding (anti-histamines, non-steroidal anti-inflammatory drugs, and certain antibiotics). Similarly, foods, beverages, and herbal medicines that can affect the platelet function or number must be avoided.
  • All patients with BSS, especially women, can suffer from iron deficiency due to excessive bleeding and should be monitored closely for the same and supplemented with iron if needed.
  • HLA-typing should be done for each patient at the time of diagnosis. All attempts should be made to procure HLA-matched platelets before transfusion.

Treatment Directed Towards Bleeding Episodes

  • Platelet transfusions – These are the first line of treatment in patients with BSS, who present with acute hemorrhage or are preparing for elective surgery. However, with each transfusion comes the risk of alloantibody formation and a minuscule risk of transmission of pathogens.

    • Transmission of bacteria – As platelets are stored at a higher temperature (20 to 24 degrees Celcius), there is always a risk of bacterial growth and transmission. The risk is much higher with whole-blood-derived platelets compared to apheresis-derived platelets.
    • Alloimmunization – HLA-matched platelets are ideal for transfusion; however, they may not be available in emergent conditions.
    • Antibodies against glycoproteins – Although this is a more common phenomenon in patients with Glanzman thrombocytopenia (GT); patients with BSS can also develop antibodies against glycoproteins that they lack.
  • Antifibrinolytic therapy – Tranexamic acid has been used successfully in the management of mucocutaneous bleeding, and menorrhagia, in conjunction with local efforts like nasal packing, compression sponges, hormonal treatment, etc. However, the use of antifibrinolytics should be avoided in patients with pulmonary hemorrhage or those with active hematuria due to the risk of formation of intraluminal clots leading to respiratory failure and renal failure, respectively.
  • Desmopressin (DDAVP) – Releases vWF from the platelets. Due to a defective GPIB-IX-V complex, the utility of DDAVP in the management of BSS is severely limited. Only anecdotal reports suggest the use of DDAVP. However, clinicians must be aware of the potential adverse effect of severe hyponatremia and seizures associated with repeated DDAVP use.

Potentially beneficial strategies not approved for patients with BSS:

  • In a small phase II clinical trial, the thrombopoietin receptor agonist, Eltrombopag, was successfully used in increasing the platelet count in patients diagnosed with inherited thrombocytopenias. One of the five patients had monoallelic BSS. Eltrombopag is not approved for treating thrombocytopenia secondary to BSS.
  • Recombinant factor VII (rfVII) has been approved for use in patients with Glanzmann’s thrombasthenia (GT), but not in patients with BSS. There are reports of successful use of rfVII in patients with BSS. The United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) 2006 guidelines and the British Society of Haematology (BSH) platelet transfusion guidelines both recommend the use of recombinant factor VII (rfVII) in patients with GT or BSS in the event of severe bleeding.
  • Allogeneic stem cell transplant has been used in patients with BSS. However, there is scarce data. This is usually reserved for patients with too many antibodies and with a severe bleeding disorder.

Pregnancy in patients with BSS requires special consideration.

  1. Counseling prospective parents: Identify potential risk factors (consanguineous marriage, parents are carriers, etc.) for the fetus to develop BSS. In women with BSS, the potential risk of hemorrhage should be discussed. Neonates will not develop homozygous BSS unless both parents are carriers.
  2. Antenatal: Manage specialized units in consultation with high-risk obstetrics and hematology. The mother should be checked for HLA type, and anti-platelet antibodies, and assessed for the risk of developing neonatal alloimmune thrombocytopenia (FNAIT).
  3. Labour: Neuraxial anesthesia is contraindicated as hemostasis cannot be guaranteed. The use of uterotonics is encouraged in the second stage of labor. HLA-matched platelets and tranexamic acid should be used if needed. The rfVII can be used in severe bleeding.
  4. Post-partum: All patients must be monitored for eight weeks, at least for bleeding symptoms.
  5. Neonates: The risk of FNAIT is high, especially in mothers diagnosed with BSS requiring multiple platelet transfusions throughout their lives. Such patients have anti-GPI antibodies that can cross the placenta and affect the normal platelets of the neonate. Monitor the blood count of neonates very closely.
  6. Genetic counseling is recommended for people with Bernard-Soulier syndrome and their families. Another treatment is symptomatic and supportive.

References

Patient safety assistant

Check your symptom safely

Hi, I am RX Symptom Navigator. I can help you understand what to read next and what warning signs need care.
Warning: Do not use this in emergencies, pregnancy, severe illness, or as a substitute for a doctor. For children or teens, use with a parent/guardian and clinician.
A rural-friendly guide: warning signs, when to see a doctor, related articles, tests to discuss, and OTC safety education.
1 Symptom 2 Severity 3 Safe guidance
First safety question

Is there chest pain, breathing trouble, fainting, confusion, severe bleeding, stroke-like weakness, severe injury, or pregnancy danger sign?

Choose quickly

Browse by body area
Start here: Write or select a symptom. The guide will show warning signs, doctor guidance, diagnostic tests to discuss, OTC safety education, and related RX articles.

Important: This tool is educational only. It cannot diagnose, treat, or replace a doctor. OTC information is not a prescription. In an emergency, contact local emergency services or go to the nearest hospital.

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Doctor / qualified healthcare provider
Tests to discuss with doctor
  • Basic vital signs: temperature, pulse, blood pressure, oxygen level if needed
  • Relevant blood, urine, imaging, or specialist tests only after clinical assessment
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Back pain care roadmap

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • New leg weakness, numbness around private area, or loss of bladder/bowel control
  • Back pain after major injury, fever, unexplained weight loss, cancer history, or severe night pain
Doctor / service to discuss: Orthopedic/spine specialist, physical medicine doctor, physiotherapist under guidance, or qualified clinician.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Discuss neurological examination first. X-ray or MRI may be needed only when red flags, injury, nerve weakness, or persistent severe symptoms are present.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.
  • Avoid forceful massage or bone-setting when there is weakness, injury, fever, or nerve symptoms.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Is this article a replacement for a doctor?

No. It is educational content only. Patients should consult a qualified clinician for diagnosis and treatment.

When should I seek urgent care?

Seek urgent care for severe symptoms, rapidly worsening condition, breathing difficulty, severe pain, neurological changes, or any emergency warning sign.

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Congenital Enterocyte Heparan Sulfate Deficiency

    Congenital? enterocyte heparan sulfate deficiency is a very rare, severe, genetic intestinal disease. In this condition, the small bowel lining cells, called enterocytes, do not show...

    April 3, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  2. Congenital ectropion uveae

    Congenital? ectropion uveae, often shortened to CEU, is a very rare eye condition present from birth. In this condition, the dark pigment layer that normally stays...

    April 2, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  3. Congenital Dyserythropoietic Anemia, Type III

    Congenital? dyserythropoietic anemia?, type III, also called CDA type III, is a very rare inherited blood disease. In this disease, the bone marrow tries to make...

    April 2, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  4. Congenital Dyserythropoietic Anemia Type I

    Congenital? dyserythropoietic anemia?, type I, usually called CDA type I, is a rare inherited blood disease. In this disease, the bone marrow tries to make red...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  5. Congenital Dyserythropoietic Anemia Due to KLF1 Mutation

    Congenital? dyserythropoietic anemia? due to KLF1 mutation is a very rare inherited red blood cell disease. In most reported cases, doctors describe it as congenital? dyserythropoietic...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  6. Congenital Dyserythropoietic Anemia Due to KLF1 Mutation

    Congenital? dyserythropoietic anemia? due to KLF1 mutation is a very rare inherited red blood cell disease. In most reported cases, doctors describe it as congenital? dyserythropoietic...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  7. HEMPAS – Hereditary Erythroblast Multinuclearity with Positive Acid Serum Test

    HEMPAS – Hereditary Erythroblast Multinuclearity with Positive Acid Serum Test is a rare inherited blood disease. Its full old name is hereditary erythroblastic multinuclearity with positive...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  8. Congenital Dyserythropoietic Anemia Type 2

    Congenital? dyserythropoietic anemia? type 2, also called CDA type II, is a rare inherited blood disease. In this disease, the body makes red blood cells in...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  9. Component of Oligomeric Golgi Complex 2–Congenital Disorder of Glycosylation

    Component of oligomeric Golgi complex 2–congenital? disorder of glycosylation is usually called COG2-CDG. It is a very rare inherited metabolic disease. In this disease, both copies...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  10. Congenital Disorder of Glycosylation, Type IIq

    Congenital? disorder of glycosylation, type IIq, is a very rare inherited metabolic disease. It is now also commonly called COG2-CDG because it is caused by harmful...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)